IN8BIO, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1 USD | -1.96% |
|
-5.66% | -27.54% |
| Apr. 30 | In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma | CI |
| Apr. 10 | Top Premarket Gainers | MT |
- Stock Market
- Equities
- INAB Stock
- News IN8bio, Inc.
- Transcripts
